<DOC>
	<DOCNO>NCT02170376</DOCNO>
	<brief_summary>The purpose study determine effect repeat dose once-daily 25 , 50 75 mg opicapone ( OPC , development code BIA 9-1067 ) levodopa pharmacokinetics ( PK ) , comparison placebo 200 mg entacapone ( ENT ) .</brief_summary>
	<brief_title>The Effect BIA 9-1067 Steady-state Levodopa Pharmacokinetics</brief_title>
	<detailed_description>This study single-centre , randomize , double-blind , gender-balanced , placebo-controlled study 4 group 20 healthy subject ( 10 male 10 female ) . The clinical part include screen examination within 3 week first institutionalization , ambulatory period 11 day ( Day 1 even Day 11 evening ) , subject return clinical unit every evening , follow institutionalization 1.5 day ( Day 11 even Day 13 morning ( i.e . 14 h third administration levodopa/carbidopa ) . Then , follow-up visit 5 9 day collection last PK blood sample ( i.e . Day 13 ) . The maximum total duration clinical study , include 21-day screening period post-study follow-up , expect 39 43 day .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Healthy male female volunteer 18 45 year old ( inclusive ) , Body Mass Index ( BMI ) normal range ( 1830 kg/m² ) , Healthy determine Investigator basis medical history , physical examination , clinical laboratory test result , vital sign , complete neurological examination 12lead ECG ( electrocardiogram ) , Negative test Hepatitis B surface antigen ( HBsAG ) , antiHepatitis C virus ( HCV ) antibodies Human immunodeficiency virus ( HIV ) 1 HIV2 antibody screen , Negative screen drug abuse alcohol screen admission treatment period , If childbearing potential ( i.e . except sterilize least 3 month postmenopausal least one year menopause define follicule stimulate hormone ( FSH ) level &gt; 30 IU/L ) : use non hormonal acceptable contraception method , i.e . intrauterine device , condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository duration study , If female childbearing potential , negative human chorionic gonadotropin ( HCG ) beta serum pregnancy test screen urinary pregnancy test admission ambulatory confinement period , Nonsmokers exsmokers least 3 month , Able communicate well Investigator research staff comply requirement entire study , Provision write informed consent participate show signature volunteer consent form , Registered French Social Security agreement French law biomedical experimentation Did conform inclusion criterion , case volunteer clinically relevant surgical history , clinically relevant family history ; history relevant atopy , Had significant infection know inflammatory process screen admission treatment period ; acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period , Were vegetarian , vegan medical dietary restriction , Could communicate reliably Investigator , Were unlikely cooperate requirement study ; history hypersensitivity OPC , tolcapone , ENT , levodopa , carbidopa , benserazide relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug , Had significant cardiovascular ( e.g . hypertension ) , hepatic , renal , respiratory ( e.g . childhood asthma ) , gastrointestinal , endocrine ( e.g . diabetes , dyslipidemia ) , immunologic , dermatological , hematological , neurological , psychiatric disease , Presented clinically significant illness previous 28 day Day 1 study ; history drug abuse within 1 year study Day 1 ; history alcoholism within 1 year Day 1 , Had take prescribed counter drug ( include antacid drug ) , exception paracetamol ( 3 g per day ) within 2 week prior dose administration , Consumed 50 g ethanol per day ( 12.5 cL glass 10° [ 10 % ] wine = 12 g ; 4 cL aperitif , 42° [ 42 % ] whiskey = 17 g ; 25 cL glass 3° [ 3 % ] beer = 7.5 g ; 25 cL glass 6° [ 6 % ] beer = 15 g , Drank 8 cup daily beverage contain caffeine , Had poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician , Had receive experimental drug within exclusion period define National Register Healthy Volunteers French Ministry Health , Forfeited freedom administrative legal award guardianship , Had undergone surgery donate blood ( i.e . 450 mL ) within 12 week study Day 1 , Had positive urine screen ethyl alcohol drug abuse upon admission treatment period , Had history tuberculosis and/or prophylaxis tuberculosis ; positive result HIV , HBsAg antiHCV test ; participation previous clinical study OPC , If female , pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson 's disease ( PD )</keyword>
	<keyword>BIA 9-1067</keyword>
	<keyword>Opicapone</keyword>
</DOC>